Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Mol Neurobiol. 2012 Nov 20;47(3):857–867. doi: 10.1007/s12035-012-8377-3

Figure 5.

Figure 5

Effect of 17β-estradiol treatments on β secratase (BACE1) in vivo and in vitro. For in vivo study, APP/OVX (n=5 each treatment) and APP/Ar+/− (n=6 each treatment) mice received 17β-estradiol (E), genistein (G) or placebo (C) at an age of 3 months until tissue was harvested at age of 12 months, and BACE1 protein and mRNA levels and activities were measured as described in methods section. (A) Effects of early treatments on BACE1 protein expression by Western blot. (B) Inhibitory effect of early treatments on mRNA levels of BACE1 by real-time PCR. (C) Effect of early and late treatments on BACE1 activity expressed by florescent unite per minute (FU/min). (D) For in vitro study, BACE1 protein expression (mean ratios of BACE1/β-actin integrated optical density values, IDV) in the APP transfected 293 cells treated with 17β-estradiol (E2) and genistein (Gen) for 48 hours with or without estrogen receptor antagonist ICI 182789. * indicates p< 0.05 compared to placebo treated APP/Ar+/− mice or DMSO treated APP transfected 293 cells. # indicates P<0.05 compared to E2 10uM and 50uM treated cells.